Novartis, Sun Settle IP Suit Over Generic Focalin
Novartis Pharma AG resolved a patent infringement suit Monday in New Jersey over Sun Pharmaceutical Industries Ltd.'s proposed generic version of Novartis' attention deficit disorder drug Focalin after receiving government approval...To view the full article, register now.
Already a subscriber? Click here to view full article